2183 Stock Overview
Provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Linical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥426.00 |
| 52 Week High | JP¥801.00 |
| 52 Week Low | JP¥374.00 |
| Beta | 0.29 |
| 11 Month Change | -0.70% |
| 3 Month Change | 7.58% |
| 1 Year Change | -45.24% |
| 33 Year Change | -52.82% |
| 5 Year Change | -58.28% |
| Change since IPO | 13.60% |
Recent News & Updates
Shareholder Returns
| 2183 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | -2.5% | -4.6% | -5.2% |
| 1Y | -45.2% | -34.8% | 15.7% |
Return vs Industry: 2183 underperformed the JP Life Sciences industry which returned -34.8% over the past year.
Return vs Market: 2183 underperformed the JP Market which returned 15.7% over the past year.
Price Volatility
| 2183 volatility | |
|---|---|
| 2183 Average Weekly Movement | 3.7% |
| Life Sciences Industry Average Movement | 5.2% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 2183 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2183's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 662 | Kazuhiro Hatano | www.linical.co.jp |
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariats; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management.
Linical Co., Ltd. Fundamentals Summary
| 2183 fundamental statistics | |
|---|---|
| Market cap | JP¥9.62b |
| Earnings (TTM) | JP¥338.00m |
| Revenue (TTM) | JP¥12.31b |
28.5x
P/E Ratio0.8x
P/S RatioIs 2183 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2183 income statement (TTM) | |
|---|---|
| Revenue | JP¥12.31b |
| Cost of Revenue | JP¥8.53b |
| Gross Profit | JP¥3.78b |
| Other Expenses | JP¥3.44b |
| Earnings | JP¥338.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 14, 2024
| Earnings per share (EPS) | 14.96 |
| Gross Margin | 30.69% |
| Net Profit Margin | 2.75% |
| Debt/Equity Ratio | 31.5% |
How did 2183 perform over the long term?
See historical performance and comparison